Researchers have developed a straightforward scoring system to predict which patients with severe asthma are most likely to achieve clinical remission after starting biologic treatment. This tool addresses a critical gap in current clinical practice, where predicting individual response to these transformative therapies has been difficult.
The study defined clinical remission through three strict criteria: no use of maintenance oral corticosteroids, zero asthma exacerbations, and an Asthma Control Test (ACT) score of at least 23. In the development cohort, approximately 38% of patients met this benchmark, with 36% achieving remission in the independent validation cohort.
Analysis identified three independent predictors for success: male sex, a baseline ACT score of 20 or higher, and the presence of comorbid chronic rhinosinusitis. These variables were combined into the MAC score, assigning one point for each factor present.
The MAC score demonstrated strong predictive accuracy across both cohorts. Because it relies solely on data routinely collected during standard consultations, it can be implemented in diverse healthcare settings without additional testing or costs. This simplicity supports shared decision-making and helps set realistic expectations for disease control.
As biologic options expand, tools like the MAC score are vital for tailoring therapy. While further studies are needed to validate the model in broader populations, this finding marks a significant step toward more precise, personalized management of severe asthma.